BioXcel Therapeutics (BTAI) Misses Q1 EPS by 22c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.84), $0.22 worse than the analyst estimate of ($1.62). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $447.1 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Morgan Stanley Upgrades Coal India Ltd (COAL:IN) to Overweight
• Raymond James Reiterates Underperform Rating on Lennar (LEN)